Genetic dissection of intratumor heterogeneity of PD-L1 expression in EGFR-mutated lung adenocarcinoma

被引:2
|
作者
Kunimasa, Kei [1 ]
Hirotsu, Yosuke [2 ]
Amemiya, Kenji [2 ]
Honma, Keiichiro [3 ]
Nakamura, Harumi [4 ]
Nishino, Kazumi [1 ]
Omata, Masao [2 ,5 ]
机构
[1] Osaka Int Canc Inst, Dept Thorac Oncol, 3-1-69 Otemae Chuoku, Osaka, Osaka 5418567, Japan
[2] Yamanashi Cent Hosp, Genome Anal Ctr, Kofu, Yamanashi, Japan
[3] Osaka Int Canc Inst, Dept Diagnost Pathol & Cytol, Osaka, Japan
[4] Osaka Int Canc Inst, Lab Genom Pathol, Osaka, Japan
[5] Univ Tokyo, Tokyo, Japan
基金
日本学术振兴会;
关键词
EGFR mutation; intratumor heterogeneity; PD-L1; expression; tumor infiltrating lymphocytes; MUTATIONS; GENOME; CELLS;
D O I
10.1111/1759-7714.15038
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study, we investigated the association between PD-L1 expression in tumor cells and underlying genetic mutations, which was analyzed in detail using laser microdissection and next-generation sequencing analysis. To investigate whether driver mutations are involved in the background of PD-L1 expression, the EGFR major activating mutation was selected as the most frequent driver mutation. Surgical resection specimens were used to extract sufficient amounts of nucleic acids for analysis, and the high tumor proportion score (TPS:100%) and low (TPS: 0%) PD-L1-expressing parts of the tumor were each laser microdissected to examine the association between PD-L1 expression heterogeneity and genetic mutations within the same tumor. The association between PD-L1 heterogeneity and gene mutations within the same tumor was investigated. Analysis showed no association between PD-L1 expression heterogeneity and genetic variants, which were found to be almost identical. However, PD-L1 expression was found to be associated with the number of tumor infiltrating lymphocytes (TILs) present in the tumor, which may be related to whether or not lymphocytes can infiltrate into the tumor depending on the tumor histological type (solid pattern, lepidic pattern, etc.) and other factors.
引用
收藏
页码:2210 / 2215
页数:6
相关论文
共 50 条
  • [41] Clinical relevance of PD-L1 expression and CD8+T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer
    Liu, Si-yang
    Dong, Zhong-yi
    Wu, Si-pei
    Xie, Zhi
    Yan, Li-xu
    Li, Yu-fa
    Yan, Hong-hong
    Su, Jian
    Yang, Jin-Ji
    Zhou, Qing
    Zhong, Wen-Zhao
    Tu, Hai-Yan
    Yang, Xue-Ning
    Zhang, Xu-Chao
    Wu, Yi-Long
    LUNG CANCER, 2018, 125 : 86 - 92
  • [42] Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression
    Minehiko Inomata
    Hiroaki Tanaka
    Kotaro Tokui
    Chihiro Taka
    Seisuke Okazawa
    Kenta Kambara
    Shingo Imanishi
    Toru Yamada
    Toshiro Miwa
    Ryuji Hayashi
    Kazuyuki Tobe
    Oncology and Therapy, 2017, 5 (2) : 181 - 185
  • [43] EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report
    Dansin, Eric
    Carnot, Aurelien
    Servent, Veronique
    Daussay, Dorothee
    Robin, Yves-Marie
    Surmei-Pintilie, Ecaterina
    Lauridant, Geraldine
    Descarpentries, Clothilde
    Revillion, Francoise
    Delattre, Claire
    CASE REPORTS IN ONCOLOGY, 2015, 8 (01): : 164 - 168
  • [44] Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma
    Hakozaki, Taiki
    Kitazono, Miyako
    Takamori, Mikio
    Kiriu, Takahiro
    INTERNAL MEDICINE, 2020, 59 (10) : 1291 - 1294
  • [45] Unique MicroRNA and mRNA Interactions in EGFR-Mutated Lung Adenocarcinoma
    Subat, Sophia
    Inamura, Kentaro
    Ninomiya, Hironori
    Nagano, Hiroko
    Okumura, Sakae
    Ishikawa, Yuichi
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (11)
  • [46] DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
    Berger, Alice H.
    Chen, Ming
    Morotti, Alessandro
    Janas, Justyna A.
    Niki, Masaru
    Bronson, Roderick T.
    Taylor, Barry S.
    Ladanyi, Marc
    Van Aelst, Linda
    Politi, Katerina
    Varmus, Harold E.
    Pandolfi, Pier Paolo
    PLOS ONE, 2013, 8 (11):
  • [47] Glucose supports EGFR-mutated lung adenocarcinoma survival by sustaining EGFR stability
    Rho, Jin Kyung
    Choi, Yun Jung
    Choi, Chang-Min
    Lee, Jae Cheol
    CANCER RESEARCH, 2016, 76
  • [48] PD-L1 Expression in Lymphovascular Tumor Emboli in Lung Adenocarcinoma
    Yeh, Y.
    Ma, H.
    Ho, H.
    Chou, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S446 - S446
  • [49] PD-L1 Expression in Primary Lung Adenocarcinoma and its Relation with EGFR / KRAS Mutation and Clinicopathological Features
    Li, L.
    Guo, C.
    Guo, L.
    Dai, H.
    Ying, J.
    Gao, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S761 - S761
  • [50] Higher Prevalence of EGFR Mutations Significantly Correlates with Lower PD-L1 Expression in Chinese Lung Adenocarcinoma
    Wen, S.
    Jiang, Y.
    Guo, J.
    Fan, X.
    Pan, X.
    Dai, Y.
    Chen, D.
    Wang, K.
    Dong, X.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S782 - S783